BACKGROUND: Low-dose metronomic (LDM) chemotherapy is a novel approach that involves frequent administration of a low dose of chemotherapeutic agent without a long interval. PURPOSE: The aim of this clinical pilot study was to evaluate the toxicity and efficacy of LDM chemotherapy with weekly low-dose docetaxel for previously treated non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: The enrolled patients received 15 mg/m2 of docetaxel intravenously on a weekly basis without any interval. RESULTS: Twenty-seven patients were enrolled in the study; 20 were men, and seven were women. The median age was 62 years (range: 32-75). Eleven patients were stage IIIB, and 16 were stage IV. The Eastern Cooperative Oncology Group performance status was 0 or 1. There was no severe hematological adverse effect; importantly, there was no neutropenia or thrombocytopenia. The objective response rate was 7.4% and the disease control rate was 51.9%. The median survival time was 16.4 months (95% CI: 5.7-36.4). CONCLUSION: Our preliminary results indicate that our metronomic regimen was well tolerated and active in patients with previously treated NSCLC. Thus, further investigation of this LDM regimen is warranted.
BACKGROUND: Low-dose metronomic (LDM) chemotherapy is a novel approach that involves frequent administration of a low dose of chemotherapeutic agent without a long interval. PURPOSE: The aim of this clinical pilot study was to evaluate the toxicity and efficacy of LDM chemotherapy with weekly low-dose docetaxel for previously treated non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: The enrolled patients received 15 mg/m2 of docetaxel intravenously on a weekly basis without any interval. RESULTS: Twenty-seven patients were enrolled in the study; 20 were men, and seven were women. The median age was 62 years (range: 32-75). Eleven patients were stage IIIB, and 16 were stage IV. The Eastern Cooperative Oncology Group performance status was 0 or 1. There was no severe hematological adverse effect; importantly, there was no neutropenia or thrombocytopenia. The objective response rate was 7.4% and the disease control rate was 51.9%. The median survival time was 16.4 months (95% CI: 5.7-36.4). CONCLUSION: Our preliminary results indicate that our metronomic regimen was well tolerated and active in patients with previously treated NSCLC. Thus, further investigation of this LDM regimen is warranted.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: M J Piccart; J Klijn; R Paridaens; M Nooij; L Mauriac; R Coleman; M Bontenbal; A Awada; J Selleslags; A Van Vreckem; M Van Glabbeke Journal: J Clin Oncol Date: 1997-09 Impact factor: 44.544
Authors: Giorgio Scagliotti; Thomas Brodowicz; Frances A Shepherd; Christoph Zielinski; Johan Vansteenkiste; Christian Manegold; Lorinda Simms; Frank Fossella; Katherine Sugarman; Chandra P Belani Journal: J Thorac Oncol Date: 2011-01 Impact factor: 15.609
Authors: F V Fossella; R DeVore; R N Kerr; J Crawford; R R Natale; F Dunphy; L Kalman; V Miller; J S Lee; M Moore; D Gandara; D Karp; E Vokes; M Kris; Y Kim; F Gamza; L Hammershaimb Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544
Authors: F A Shepherd; J Dancey; R Ramlau; K Mattson; R Gralla; M O'Rourke; N Levitan; L Gressot; M Vincent; R Burkes; S Coughlin; Y Kim; J Berille Journal: J Clin Oncol Date: 2000-05 Impact factor: 44.544
Authors: Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn Journal: J Clin Oncol Date: 2004-05-01 Impact factor: 44.544